Zheng Quan Shi Bao Wang·2025-07-31 01:09Core Viewpoint - Danno Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities and Agricultural Bank of China International as joint sponsors [1] Company Overview - Danno Pharmaceuticals is a biotechnology company focused on the research and development of innovative drugs aimed at addressing unmet clinical needs in the fields of bacterial infections and bacterial metabolism-related diseases [1] Key Products - The company has three core products: - Rifaterinazole (TNP-2198) - TNP-2092 injection - TNP-2092 oral formulation [1] Product Details - Rifaterinazole (TNP-2198) is the world's first and only new molecular entity candidate drug for the treatment of Helicobacter pylori infection, featuring a unique dual bactericidal mechanism that may overcome antibiotic resistance [1] - Danno Pharmaceuticals has completed a head-to-head Phase III clinical trial comparing the Rifaterinazole triple therapy (RTT) with the bismuth quadruple therapy (BQT) in China, showing that RTT outperforms BQT in terms of eradication rate, safety, and tolerability, particularly in populations with multiple drug resistance [1] Regulatory Plans - The company plans to submit a new drug application for Rifaterinazole to the National Medical Products Administration by the end of August 2025 [1] - Rifaterinazole has received IND approval, Fast Track designation, and QIDP recognition from the US FDA, which is expected to expedite its market entry in the US and other overseas markets [1]